

CURRICULUM VITAE

JORGE G. OTOYA, M.D.

PERSONAL:

Office Name
& Address:

Osceola Cancer Center
1300 W. Oak Street
Kissimmee, FL 34741
(407) 933-2775 (866) 250-4679
Fax #: (407) 933-8549

MEDICAL EDUCATION:

University of San Marcos
Lima, Peru
Doctor of Medicine

November 16, 1976

University of San Marcos
Lima, Peru
General Surgery Residency

January 1977 – December 1979

University of Miami School of Medicine
Center for Blood Diseases
Latin American Program
Miami, Florida
Research Fellow

July 1981 – June 1984

POSTGRADUATE EDUCATION:

New Hanover Memorial Hospital
Wilmington, North Carolina
Internal Medicine Internship

July 1984 – June 1986

St. Francis Hospital
Evanston, Illinois
Internal Medicine Residency

July 1986 – June 1988

FELLOWSHIPS:

St. Francis Hospital
 Evanston, Illinois
 Hematology / Oncology

July 1988 – June 1991

CERTIFICATIONS:

Educational Commission for Foreign
 Medical Graduates

1983

Federation Licensing Examination

1986

American Board of Internal Medicine

1989

American Board of Internal Medicine
 Medical Oncology

1998

American Board of Internal Medicine
 Hematology

1999

PROFESSIONAL ORGANIZATIONS:

Pan American Medical Society
 Peruvian Medical Association
 American Society of Clinical Oncology
 American Society of Hematology
 American College of Physicians

LICENSES:

Illinois – 1986

Florida – 1991

MEDICAL PRACTICE EXPERIENCE:

Osceola Cancer Center
 1300 W. Oak Street
 Kissimmee, FL 34741

July 1991 – Present

PROFESSIONAL ACTIVITIES:

Past member, Tumor Board
Florida Hospital East

Co-Chair, Cancer Committee
Osceola Regional Hospital

Member, Quality Council
Osceola Regional Hospital

Past Chairman, Cancer Committee
Osceola Regional Hospital

Past member, Hematology & Oncology Committee
Florida Hospital

Past member, Board of Directors
Leukemia Society
Orlando, Florida

Past member, Tissue & Transfusion Committee
Princeton Hospital
Orlando, Florida

Past member, Case Review Committee
Osceola Regional Hospital
Kissimmee, Florida

Secretary, PanAmerican Medical Association
Orlando, Florida 1998

Scientific Program Chairman, PanAmerican
Medical Association
Orlando, Florida 1998

President, Pan American Medical Association
Orlando, Florida 1999

Vice President, Pan American Medical Assoc.
Orlando, Florida 2000

Chairman, Medicine Department
Florida Hospital Kissimmee 1999

INTERESTS:

Swimming

RESEARCH EXPERIENCE:

Investigator, Cancer and Leukemia Group B (CALGB) and National Surgical Adjuvant Bowel Project (NSABP), Walt Disney Memorial Cancer Institute, Florida Hospital, Orlando, Florida in cooperation with Duke University, Orlando, Florida. 1993.

Investigator, Radiation Therapy Oncology Group (RTOG), Osceola Regional Hospital, Kissimmee, Florida in cooperation with John Hopkins Hospital, 1993.

Sub-Investigator, Faulding Pharmaceuticals, Inc./ Harris Laboratories, Protocol CDD-14556, "A randomized double-blind, Parallel Group Study comparing the Efficacy and Safety of Kapanol to MS Contin in the Management of Patients with Moderate to Severe Cancer Pain", July 1993 – October 1994.

Principal Investigator, Amgen, Inc., Research Protocol PR 93-27-003, "Procrit (Epoetin Alfa): Phase IV Clinical Evaluation in Anemic Patients receiving Chemotherapy", September 1993 to May 1994.

Sub-Investigator, ZENEA Pharmaceutical Group, Protocol 1033IL/0004, "A randomized, Multi-center, Efficacy and Safety Study to Evaluate Arimidex 1 and 10 mg. Double-blind, compared to Open Label Megace in Post menopausal Women and Advanced Breast Cancer", February 1995 to 1997.

Sub-Investigator, The Purdue Frederick Company, Protocol OC93-0202, "double-blind, randomized, Two-Period Crossover Efficacy comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Immediate release Oxycodone and controlled release Oxycodone in cancer patients with Pain", March 1994 to January 1995.

Sub-Investigator, Purdue Frederick Company, Protocol OC92-1101, "Open-Label clinical use of study of Controlled release Oxycodone tablets Administered orally every 12 hours for the management of pain", March 1994.

Sub-Investigator, Pharmacia Inc., Protocol 12002, "Efficacy Trial of FCE 24304 (Exemestane) in the Treatment of Postmenopausal Patients with Metastatic Breast Cancer Failing Tamoxifen", June 1994.

Sub-Investigator, Pharmacia, Inc., Protocol 12004, "Anti-tumor Efficacy Trial of FCE 24304 (Exemestane) as third line Hormonal Therapy in the Treatment of Postmenopausal Women with Metastatic Breast Cancer Refractory to Tamoxifen and Megace", June 1994 to November 1995.

Sub-Investigator, Pharmacia, Inc., Protocol 129004, “Anti-tumor Efficacy Trial of FCE 24517 (Tallimustine) in the Treatment of Adult patients with Renal Cell Carcinoma”, September 1994 to August 1995.

Sub-Investigator, Pharmacia, Inc., Protocol 129005, “Anti-tumor Efficacy Trial of FCE 24517 (Tallimustine) in the Treatment of Adult Patients with Adenocarcinoma of the Stomach or Gastro-Esophageal Junction”, September 1994 to August 1995.

Sub-Investigator, Pharmacia, Inc., Protocol 129006, “Anti-tumor Efficacy Trial of FCE 24517 (Tallimustine) in the treatment of Adult Patients with Carcinoma of the Pancreas”, September 1994 to August 1995.

Sub-Investigator, The Purdue Frederick Company, Protocol OC91-1001, “double-blind, Randomized 12H, Multiple dose, Parallel Group Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Controlled-Release Oxycodone (Oxycontin) and MS Contin Tablets in Patients with Chronic Cancer Related pain”, November 1994 to September 1995.

Sub-Investigator, Roberts Pharmaceutical, Protocol 38,584-301B, “An open Controlled Study of Deslorelin for the Treatment of Stage D2 Prostate Cancer”, March 1995 to May 1995.

Sub-Investigator,hone Poulenc Rorer Protocol 60180X-204A, “A randomized Double blind Parallel Group single Comparative Study of RO60180 (0.5 mg and 7.5 mg) and Morphine Sulphate (20 mg) in patients with cancer pain”, March 1995 to May 1995.

Sub-Investigator, SoloPak Pharmaceuticals, Inc., Protocol SP-MM-01, “A randomized double-blind, Multi-center Study of Low-dose Gallium Nitrate for Treatment of Bone Involvement due to Multiple Myeloma’, August 1995 to 1997.

Principal Investigator Genetech, In., Protocol H2251n, “Clinical outcomes in patients with HER2 Gene-Amplified Metastatic Breast Cancer Treated with First-line Herceptin in combination with a Taxane: A phase IV Prospective, Community-Based study”, July 2001 to present.

Sub-investigator, Novartis Pharmaceuticals Corp. Protocol CZOL446EUS16, “A Prospective, Multicenter, Open-Label Clinical Evaluation of the Effect of I.V. Zometa 4mg on Pain, Quality of Life and Time in Infusion Chair in Breast Cancer, Multiple Myeloma and Prostate Cancer Patients with Cancer-Related Bone Lesions:, October 2001 to September 2002.

Sub-investigator, Pharmacia, Inc., Protocol 378-ONC-0030-184, “Phase III Study of Epirubicin/Cyclophosphamide Followed by Taxane (Sequential Chemotherapy) versus Epirubicin / Taxane (Concurrent Chemotherapy) as Adjuvant Treatment for Operable, Node-Positive Breast Cancer”, October 2001 to Present

Sub-investigator, Amgen, Protocol NESP 20000220, “An Open-Label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy and Darbeoetin alfa (NESP)”, October 2001 to present.

Sub-investigator, Roche Pharmaceuticals, Protocol XEL-154, “ A Pilot Trial of Two Different Doses of Capecitabine (XELODA) in Patients with Advanced and/or Metastatic Breast Cancer”, November 2001 to present.

Sub-investigator, Amgen, Protocol NEXP 20000219, “A randomized, Open-Label, Comparative Study to estimate the Effect of Darbepoetin alfa on Hospital Days, Economic Outcomes and Health-Related Quality of Life in subjects with Nonmyeloid Malignancies and Anemia of Cancer”, November 2002 to present.

Revised 11-01

Revised 9-02

Revised 11-02

